quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:35:00·78d
PRRelease
Adial Pharmaceuticals Inc logo

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

ADIL· Adial Pharmaceuticals Inc
Health Care
Original source

Companies

  • ADIL
    Adial Pharmaceuticals Inc
    Health Care

Recent analyst ratings

  • Nov 14UpdateRodman & Renshaw$8.00
  • Oct 13UpdateBrookline Capital$12.00
  • Jun 29UpdateLitchfield Hills$5.00

Related

  • PR1d
    Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
  • INSIDER14d
    SEC Form 4 filed by Anderson J. Kermit
  • SEC14d
    Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • INSIDER14d
    SEC Form 4 filed by Goodman Tony
  • INSIDER14d
    SEC Form 4 filed by Shah Vinay
  • INSIDER14d
    SEC Form 4 filed by Schuyler Kevin
  • INSIDER14d
    SEC Form 4 filed by Claiborne Cary J
  • INSIDER14d
    SEC Form 4 filed by Gilliland Robertson H.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022